Praveen Tipirneni's team at Morphic reels in an $80M round as they turn into the last stretch to the clinic — and a deal
As a former business development guy at Cubist, Praveen Tipirneni got to know the routine about the due diligence work BD teams are known for during a negotiation.
“People poke holes,” he says. It could be about an assay, something that was being hyped beyond reality or a program that was presented at a certain stage which may not quite be there yet.
But you have to find those holes.
Now that he’s on the CEO side of the bargaining table, though, one of only two people on Morphic Therapeutic’s 37-member team not devoted entirely to research, he’s more than a little pleased that the partners he’s talking with haven’t been balking over any holes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.